Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business press...

Dr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Dr Reddy’s shares fell after Goldman Sachs and Citigroup turned cautious, citing limited growth visibility, pipeline concerns and valuation...

The Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the Marc...

The steady generic pricing is a tailwind and execution of key launches like gAbraxane for Cipla will determine the path of US sales in 2025.

Pharma stocks have gained investor interest as the Nifty Pharma index reaches new highs. Amid economic uncertainties, defensive sectors lik...

Alembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by stro...

"The complaint, which purports to be on behalf of a class of indirect purchasers, asserts claims under federal and state antitrust laws and...

The Hyderabad-based drug maker on Friday reported its highest ever revenues, largely driven by generic Revlimid launch during the second qu...

"We are pleased with the first-to-market launch of two of our six strengths of Lenalidomide Capsules with 180-day market exclusivity. Bring...

Revlimid is a top-selling cancer drug from Bristol Myers Squibb. Its generic form, called lenalidomide, is seen as Dr Reddy's most anticipa...

Revlimid had annual sales of $2.3 billion as of December 2021, according to IQVIA data. The generic version of Revlimid will be available i...

"We are pleased with the Agency's approval of Lenalidomide Capsules, 2.5 mg and 20 mg and being eligible for 180-day market exclusivity. We...

Drug major Sun Pharma has reached an agreement with Celgene Corporation, to resolve the patent litigation regarding generic version of Revl...

Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a licensc to Celgene’s patents required to manufacture and sell (sub...

US-based biotech firm Celgene, the innovator, has declined to make the drug samples available to DRL for bio-equivalence studies.